Psoriatic Arthritis Therapeutics Market Size, Share, And Growth Report 2032

Psoriatic Arthritis Therapeutics Market: Size

The global Psoriatic Arthritis Therapeutics Market size was worth around USD 11.23 billion in 2023 and is predicted to grow to around USD 25.62 billion by 2032 with a compound annual growth rate (CAGR) of roughly 9.6% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Psoriatic Arthritis Therapeutics Market on a global and regional level.

Request Free Sample

Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis is a condition prevalent in psoriasis patients and involves inflammatory arthropathy. This leads to swelling, stiffness, and tenderness of joints caused by the degeneration of cartilage bones in the joints. Sometimes, lesions may appear later than joints problems. This is a non-curable condition, but controlling the symptoms can prevent joint damage. Psoriatic arthritis is caused by abnormal immune responses, which leads to joint inflammation and overproduction of skin cells. Psoriatic arthritis can affect any body part and cause swollen and painful joints that feel warm when touched. Some symptoms include swelling in fingers and toes with deformities, pain in the foot and lower back, etc. This condition can be easily diagnosed with the help of physical examinations, blood tests, and X-rays.

The global psoriatic arthritis therapeutics market is mainly driven by the increased prevalence of psoriasis that is leading to the rise in the number of psoriatic arthritis patients. As per the National Psoriasis Foundation report, in 2018, around 10 to 30% percent of people with psoriasis developed psoriatic arthritis. Furthermore, increasing use of biologics, growing R&D activities of pipeline drugs, rising disease awareness among people coupled with a large population with unmet needs is also expected to propel the global psoriatic arthritis therapeutics market. However, stringent regulatory approval process, high cost of drugs, and lack of proper diagnosis of psoriatic arthritis may hamper the psoriatic arthritis therapeutics market globally over the projected time period.

Request Free Sample

Psoriatic Arthritis Therapeutics Market: Segmentation

The study provides a decisive view of the psoriatic arthritis therapeutics market by segmenting it based on drug class, disease type, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

By drug class, the market is fragmented into interleukin inhibitors, TNF inhibitors, PDE4 inhibitors, and others. TNF inhibitors are expected to dominate the global psoriatic arthritis therapeutics market in the future.

By disease type, the market is categorized into asymmetric psoriatic arthritis, spondylitis, distal interphalangeal predominant (DIP) psoriatic arthritis, symmetric psoriatic arthritis, and arthritis mutilans.

The distribution channel includes hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies are expected to account for the largest market share and grow significantly over the estimated timeframe.

Psoriatic Arthritis Therapeutics Market: Report Scope

Psoriatic Arthritis Therapeutics Market: Regional Analysis

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the psoriatic arthritis therapeutics market globally over the forecast time period, owing to the increasing adoption of biologic drugs for arthritis treatment and rising prevalence of psoriatic arthritis. The Asia Pacific psoriatic arthritis therapeutics market is expected to grow notably in the future, due to the presence of developing economies of India and China and increasing healthcare facilities across the region.

Psoriatic Arthritis Therapeutics Market: Competitive Players

Some major players of the global psoriatic arthritis therapeutics market include:

• AbbVie
• Amgen
• Celgene Corporation
• Janssen Biotech
• UCB
• Pfizer
• Biogen
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb

The Global Psoriatic Arthritis Therapeutics Market is segmented as follows:

Global Psoriatic Arthritis Therapeutics Market: Drug Class Analysis

• Interleukin Inhibitors
• TNF Inhibitors
• PDE4 Inhibitors
• Others

Global Psoriatic Arthritis Therapeutics Market: Disease Type Analysis

• Asymmetric Psoriatic Arthritis
• Symmetric Psoriatic Arthritis
• Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis
• Spondylitis
• Arthritis Mutilans

Global Psoriatic Arthritis Therapeutics Market: Distribution Channel Analysis

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa